Ben Nacev, MD PhD

Between this and the recent pembro trial it has been a good few months for KS clinical data

A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma. 11505Background: Kaposi sarcoma (KS), caused by Kaposi sarcoma herpesvirus (KSHV), is a multicentric angioproliferative tumor seen in people with and without HIV. Abemaciclib (abema) is an oral cyclin...

I was excited about these data for CDK4/6 inhibition in KS. > 70% PR. ascopubs.org/doi/10.1200/...

Thanks to @seppobauer.bsky.social at the #FORTRESS meeting for the push to join this community. Taking the time on the flight back home from great in person interactions at the meeting to set up the account to keep up the virtual interactions with the #sarcoma community!